Fazli L - Search Results

1

THEM6-mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer.

Blomme A, Peter C, Mui E, Rodriguez Blanco G, An N, Mason LM, Jamieson LE, McGregor GH, Lilla S, Ntala C, Patel R, Thiry M, Kung SHY, Leclercq M, Ford CA, Rushworth LK, McGarry DJ, Mason S, Repiscak P, Nixon C, Salji MJ, Markert E, MacKay GM, Kamphorst JJ, Graham D, Faulds K, Fazli L, Gleave ME, Avezov E, Edwards J, Yin H, Sumpton D, Blyth K, Close P, Murphy DJ, Zanivan S, Leung HY. Blomme A, et al. Among authors: fazli l. EMBO Mol Med. 2022 Mar 7;14(3):e14764. doi: 10.15252/emmm.202114764. Epub 2022 Jan 11. EMBO Mol Med. 2022. PMID: 35014179 Free PMC article.

2

Regulation of tumor angiogenesis by integrin-linked kinase (ILK).

Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K, Wheeler J, Gleave M, Sanghera J, Dedhar S. Tan C, et al. Among authors: fazli l. Cancer Cell. 2004 Jan;5(1):79-90. doi: 10.1016/s1535-6108(03)00281-2. Cancer Cell. 2004. PMID: 14749128 Free article.

3

Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.

July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME. July LV, et al. Among authors: fazli l. Mol Cancer Ther. 2004 Mar;3(3):223-32. Mol Cancer Ther. 2004. PMID: 15026542

4

Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.

Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K, Gleave M. Rocchi P, et al. Among authors: fazli l. Cancer Res. 2004 Sep 15;64(18):6595-602. doi: 10.1158/0008-5472.CAN-03-3998. Cancer Res. 2004. PMID: 15374973

5

Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.

Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L, Gleave ME, Cox ME. Krueckl SL, et al. Among authors: fazli l. Cancer Res. 2004 Dec 1;64(23):8620-9. doi: 10.1158/0008-5472.CAN-04-2446. Cancer Res. 2004. PMID: 15574769

6

Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate.

Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE. Knudsen BS, et al. Among authors: fazli l. Am J Pathol. 2005 Jul;167(1):255-66. doi: 10.1016/S0002-9440(10)62970-7. Am J Pathol. 2005. PMID: 15972969 Free PMC article.

7

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. Chi KN, et al. Among authors: fazli l. J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96. doi: 10.1093/jnci/dji252. J Natl Cancer Inst. 2005. PMID: 16145049 Clinical Trial.

8

Cyclin G-associated kinase: a novel androgen receptor-interacting transcriptional coactivator that is overexpressed in hormone refractory prostate cancer.

Ray MR, Wafa LA, Cheng H, Snoek R, Fazli L, Gleave M, Rennie PS. Ray MR, et al. Among authors: fazli l. Int J Cancer. 2006 Mar 1;118(5):1108-19. doi: 10.1002/ijc.21469. Int J Cancer. 2006. PMID: 16161052

9

A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.

Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, Gleave ME. Yamanaka K, et al. Among authors: fazli l. Mol Cancer Ther. 2005 Nov;4(11):1689-98. doi: 10.1158/1535-7163.MCT-05-0064. Mol Cancer Ther. 2005. PMID: 16275990

10

Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.

Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, Gleave M. Rocchi P, et al. Among authors: fazli l. Cancer Res. 2005 Dec 1;65(23):11083-93. doi: 10.1158/0008-5472.CAN-05-1840. Cancer Res. 2005. PMID: 16322258

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

270 results

Search Page

Filters